HTX-001 / HAYA Therap - LARVOL DELTA

A WISPER from the Heart: Targeting a Cardiac Myofibroblast-specific LncRNA to Treat Cardiac Fibrosis (ASGCT 2025) - "Pharmacokinetic and pharmacodynamic data indicate that preclinical and development candidates possess suitable drug-like characteristics, including dose-dependent target engagement in cardiac tissue, modulation of related circulating biomarkers and safety. These findings position a Wisper targeting therapy and HTX-001 as a promising and targeted approach with the potential to address the core issue of myocardial fibrosis in patients with HCM and other forms of heart failure."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hypertrophic Cardiomyopathy • Immunology

HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies (Businesswire) - "HAYA Therapeutics, SA...today announced that Innosuisse, the Swiss Innovation Agency, is supporting two research collaboration projects between HAYA and the University of Bern, University Hospital of Bern and Lausanne University Hospital. Innosuisse is funding 50 percent of the total project costs of approximately CHF 3.1 million (US$3.3 million). The first project will advance HAYA’s lead program, an antisense oligonucleotide targeting the lncRNA Wisper....In collaboration with the Department for BioMedical Research at University of Bern and the Department of Cardiology at University Hospital of Bern (Inselspital), the two-year project will be focused on dosing studies, pharmacodynamics, and pharmacokinetics for this first-in-class therapeutic target for the potential treatment of non-obstructive hypertrophic cardiomyopathy."

Financing • Cardiomyopathy • Cardiovascular • Non-obstructive Hypertrophic Cardiomyopathy